Latest Headlines

Latest Headlines

Genentech plucks rights to Afraxis drug assets in $187M deal

Primarily known for its work on Fragile X, a well-known autism target, Afraxis says that the giant Roche subsidiary will pay up to $187.5 million in milestones and an undisclosed upfront in order to develop the compounds for a "novel target."

NIH buddies with Afraxis to escort Fragile X program through "valley of death"

San Diego-based Afraxis is getting some key support from the National Institutes of Health as it journeys through the dreaded "valley of death" with an experimental program for Fragile X syndrome--a